Intellia Therapeutics (NASDAQ:NTLA) Releases Earnings Results, Beats Expectations By $0.16 EPS

Intellia Therapeutics (NASDAQ:NTLA) posted its earnings results on Thursday. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16, Briefing.com reports. The firm had revenue of $23.02 million for the quarter, compared to analysts’ expectations of $12.17 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The company’s quarterly revenue was up 78.4% on a year-over-year basis. During the same period last year, the firm earned ($1.27) EPS.

Here are the key takeaways from Intellia Therapeutics’ conference call:

• The company expects a pivotal readout for lonvo-z by mid?year with a planned BLA submission in the second half of the year, positioning it as potentially the world’s first pivotal in vivo CRISPR gene?editing readout.
• Commercial preparations for lonvo-z are underway—field medical hires, payer engagement, validated CMC/commercial manufacturing, and market research showing very high patient and HCP interest—which the company says could enable a launch and meaningful revenue that materially reduces future capital needs.
• The nex?z ATTR program remains disrupted by a clinical hold on the MAGNITUDE cardiomyopathy trial following liver enzyme elevations and a patient death; MAGNITUDE?2 (polyneuropathy) was reopened with added liver monitoring, steroid?trigger guidance, and tighter screening, while MAGNITUDE is still under active FDA discussion.
• Financials show cash, cash equivalents, and marketable securities of $605.1 million at year?end (down from $861.7M), which management says should fund operations into H2 2027 and support key milestones despite a Q4 net loss of $95.8M.

Intellia Therapeutics Trading Up 6.4%

NTLA stock traded up $0.86 during mid-day trading on Thursday, reaching $14.28. The company’s stock had a trading volume of 4,890,264 shares, compared to its average volume of 3,275,201. The company’s 50 day moving average is $11.80 and its two-hundred day moving average is $13.00. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The stock has a market cap of $1.65 billion, a PE ratio of -3.34 and a beta of 2.10.

Wall Street Analyst Weigh In

Several analysts have commented on the company. JonesTrading lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 11th. Robert W. Baird set a $7.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, January 27th. HC Wainwright boosted their price target on shares of Intellia Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, January 28th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 18th. Finally, KeyCorp set a $25.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, January 28th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $17.48.

Insider Activity

In other Intellia Therapeutics news, CEO John M. Leonard sold 34,146 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the sale, the chief executive officer directly owned 1,013,339 shares in the company, valued at $9,332,852.19. This represents a 3.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares in the company, valued at approximately $907,488.93. This represents a 7.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 53,051 shares of company stock worth $488,600 over the last ninety days. Corporate insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Ameriprise Financial Inc. raised its stake in shares of Intellia Therapeutics by 13.9% in the 2nd quarter. Ameriprise Financial Inc. now owns 11,803 shares of the company’s stock valued at $111,000 after acquiring an additional 1,443 shares during the period. AlphaCentric Advisors LLC purchased a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $98,000. First Trust Advisors LP acquired a new stake in Intellia Therapeutics in the 2nd quarter valued at approximately $96,000. Amundi purchased a new stake in Intellia Therapeutics in the fourth quarter valued at approximately $91,000. Finally, Insigneo Advisory Services LLC purchased a new stake in Intellia Therapeutics in the fourth quarter valued at approximately $90,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 beat — Intellia reported a narrower-than-expected loss (EPS -$0.83 vs. -$0.99 est.) and revenue of $23.02M (well above estimates), with revenue up ~78% year-over-year; that earnings surprise is a key catalyst for the stock. Intellia Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: Strong cash runway — Intellia ended 2025 with approximately $605M in cash, providing runway to advance multiple programs and de-risk near-term milestones. This cash position supports R&D and commercial preparation. Q4 & Full-Year 2025 Financial Results
• Positive Sentiment: Clear near-term commercial path for lonvo?z — Management guided to HAELO Phase 3 data by mid?2026, a potential BLA submission in 2H?2026 and U.S. launch in 1H?2027, which could materially re-rate the company if successful. Business Updates & Timelines
• Neutral Sentiment: Management tone and strategic updates from the earnings call emphasized clinical progress, commercial readiness and long-term CRISPR strategy—helpful context but dependent on upcoming data and approvals. Earnings Call Transcript
• Negative Sentiment: Regulatory risk: an FDA clinical hold remains for the MAGNITUDE Phase 3 trial of nex?z in ATTR?CM; management is engaging FDA but resolution timing is uncertain and could delay or impair that program’s value. Earnings Call Highlights & Regulatory Update
• Negative Sentiment: Profitability risk: despite the quarter-over-quarter improvement, Intellia remains unprofitable with large negative margins and analyst forecasts calling for steep net losses ahead, leaving the stock sensitive to R&D setbacks or slower-than-expected commercial progress. Zacks Q4 Coverage

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.